These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22878339)

  • 1. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
    Schafer JJ; Short WR
    Antivir Ther; 2012; 17(8):1495-502. PubMed ID: 22878339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
    Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
    Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Resistance profile of rilpivirine].
    Imaz A; García F; di Yacovo S; Llibre JM
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.
    Kulkarni R; Babaoglu K; Lansdon EB; Rimsky L; Van Eygen V; Picchio G; Svarovskaia E; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):47-54. PubMed ID: 21997204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy.
    Imaz A; Podzamczer D
    AIDS Rev; 2012; 14(4):268-78. PubMed ID: 23258301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
    Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
    AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological properties of rilpivirine (Edurant Tablet), a new drug for the treatment of HIV, and results of its clinical studies].
    Iwata M; Shikinami K; Nagino K; Harada Y
    Nihon Yakurigaku Zasshi; 2013 Apr; 141(4):205-11. PubMed ID: 23575426
    [No Abstract]   [Full Text] [Related]  

  • 14. Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
    Vingerhoets J; Rimsky L; Van Eygen V; Nijs S; Vanveggel S; Boven K; Picchio G
    Antivir Ther; 2013; 18(2):253-6. PubMed ID: 22951490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rilpivirine. First-line treatment of HIV infection: efavirenz is better documented.
    Prescrire Int; 2012 Nov; 21(132):262-5. PubMed ID: 23210255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rilpivirine: drug profile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor.
    Ripamonti D; Bombana E; Rizzi M
    Expert Rev Anti Infect Ther; 2014 Jan; 12(1):13-29. PubMed ID: 24308712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
    James C; Preininger L; Sweet M
    Am J Health Syst Pharm; 2012 May; 69(10):857-61. PubMed ID: 22555080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
    Xu HT; Colby-Germinario SP; Huang W; Oliveira M; Han Y; Quan Y; Petropoulos CJ; Wainberg MA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5649-57. PubMed ID: 24002090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.
    Sharma M; Saravolatz LD
    J Antimicrob Chemother; 2013 Feb; 68(2):250-6. PubMed ID: 23099850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.
    Molina JM; Clumeck N; Orkin C; Rimsky LT; Vanveggel S; Stevens M;
    HIV Med; 2014 Jan; 15(1):57-62. PubMed ID: 23980523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.